Study Details

Back to Search Results

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder

Other
All other study statuses such as canceled or terminated

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05062577

Astellas Study ID

The unique identification code given by the study sponsor.

8062-CL-2221

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Opioid Drug Abuse

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - 65 Years

Sex

Female & Male

Product

ASP8062

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2021 - Feb 2023

Masking

Triple (Participant, Investigator, Outcomes Assessor)

Enrollment number

0

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Pahl Pharmaceutical Professionals LLC

Oklahoma, United States, 73112

Hassman Research Institute

Berlin, United States, 08009

Innovative Clinical Research, Inc.

Lauderhill, United States, 33319

Segal Trials Miami Lakes Medical Research

Miami Lakes, United States, 33016

Accel Research Sites

Lakeland, United States, 33803

Collaborative Neuroscience net

Garden Grove, United States, 92845

Woodland International Research

Little Rock, United States, 72211

North Star Medical Research

Middleburg Heights, United States, 44130

Pillar Clinical Research

Richardson, United States, 75080

Artemis Institute for Clinical Research

San Diego, United States, 92103

Altea Research

Las Vegas, United States, 89102

Advanced Research for Health Improvement, LLC

Naples, United States, 34102

Revival Research Institute

Dearbon, United States, 48126

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo